Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 2/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 3/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PDE8A | O60658 | 2/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30301694 | 1.00 | CDK1 (0.50) | CDK1HRH4HTTDHFRPDE2A | |
| SCHEMBL14286510 | 0.81 | HRH4 (0.54) | CDK1HRH4DHFRPIK3CB | |
| SCHEMBL2173385 | 0.81 | CDK1 (0.37) | CDK1HRH4PDE2APDK1PDK2 | |
| SCHEMBL19684529 | 0.79 | HRH4 (0.42) | HRH4DHFRPIK3CBPRKCI | |
| SCHEMBL31514720 | 0.78 | GAA (0.36) | CDK1HRH4PDE2APDK1PDK2 | |
| SCHEMBL28904493 | 0.78 | GAA (0.36) | CDK1HRH4PDE2APDK1PDK2 | |
| SCHEMBL20350562 | 0.77 | CDK1 (0.39) | CDK1HRH4HTTPDE2ACFTR | |
| SCHEMBL6222598 | 0.75 | NOTUM (0.36) | CDK1HRH4PDE2APDK1PDK2 | |
| SCHEMBL20350724 | 0.75 | CDK1 (0.37) | CDK1HTTDHFRPDE2APDE8A | |
| SCHEMBL8151262 | 0.74 | HRH4 (0.51) | HRH4DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023071998-A1 | NOVEL PYRIDO OR TRIAZINE-SUBSTITUTED PYRIDO HETEROCYCLIC COMPOUND | 杭州德睿智药科技有限公司 | 2023-05-04 | — | — | WO | disclosed |
| WO-2023071998-A1 | NOVEL PYRIDO OR TRIAZINE-SUBSTITUTED PYRIDO HETEROCYCLIC COMPOUND | 杭州德睿智药科技有限公司 | 2023-05-04 | — | — | WO | disclosed |
| EP-3573992-B1 | SUBSTITUTED BICYCLIC PYRIMIDINE-BASED COMPOUNDS AND COMPOSITIONS AND USES THEREOF | TSANTRIZOS YOULA S (CA) | 2022-04-13 | — | — | EP | disclosed |
| US-11279719-B2 | Substituted bicyclic pyrimidine-based compounds and compositions and uses thereof | Tsantrizos, Youla S. (CA) | 2022-03-22 | — | — | US | disclosed |
| US-11279719-B2 | Substituted bicyclic pyrimidine-based compounds and compositions and uses thereof | Tsantrizos, Youla S. (CA) | 2022-03-22 | — | — | US | disclosed |
| CN-110573518-A | Substituted bicyclic pyrimidinyl compounds, compositions and uses thereof | 尤拉·S·赞特里佐斯 | 2019-12-13 | — | — | CN | disclosed |
| WO-2018137036-A1 | SUBSTITUTED BICYCLIC PYRIMIDINE-BASED COMPOUNDS AND COMPOSITIONS AND USES THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY (CA) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018137036-A1 | SUBSTITUTED BICYCLIC PYRIMIDINE-BASED COMPOUNDS AND COMPOSITIONS AND USES THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY (CA) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018119284-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279719-B2 | Substituted bicyclic pyrimidine-based compounds and compositions and uses thereof | GGPS1, TYMP, FDPS | CDK1 617/4885HRH4 3686/4885HTT 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.